47 citations
,
November 2012 in “Expert Opinion on Therapeutic Patents” The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
451 citations
,
March 2005 in “Endocrine Reviews” This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.
32 citations
,
January 1990 in “Clinical Endocrinology” This study found that women with female pattern androgenic alopecia have significantly higher levels of certain androgens and androgen sulfates compared to normal premenopausal women, suggesting markers for diagnosis and treatment efficacy.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” This study reports that 2-(1-Adamantyl)-4H-thiochromen-4-on-6-O-sulfamate is the most potent steroid sulfatase inhibitor identified so far, exhibiting 170-fold higher activity than the lead compound estrone sulfamate.
83 citations
,
July 2008 in “Current Opinion in Chemical Biology” This review discusses the structural and functional advances in understanding sulfotransferases and sulfatases, highlighting new insights into enzyme mechanisms and inactivation by clinically relevant aryl sulfamates, but provides no new experimental results.